Stockreport

Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF In a phase Ib/II investigational study of duvelisib, a dual inhibitor of PI3K-d,? in combination with FCR (dFCR) for frontline therapy of younger CLL pat [Read more]